PFE (Pfizer Inc.) posts 14.3 percent Q4 2025 EPS beat, stock rises 1.25 percent in regular trading. - Community Exit Signals

Pfizer Inc. (NYSE:PFE) Receives Average Recommendation of "Hold" from Brokerages

PFE (Pfizer Inc.) registra un BPA del 14,3 por ciento en el cuarto trimestre de 2025, las acciones suben un 1,25 por ciento en las operaciones regulares. - Señales de…

Pfizer marks 350 straight quarterly dividends with $0.43 payout

Pfizer Inc. Declares Second-Quarter Cash Dividend on Common Stock for 2026, Payable June 12, 2026

Pfizer Inc. $PFE Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH

Pfizer Could Surprise Again This Earnings Season (Preview) (NYSE:PFE)

Pfizer GLP-1 weight loss drug available for pre-order in China

Pfizer Lyme Disease Vaccine Shows Over 70 Percent Efficacy

Pfizer GLP-1 weight loss drug available for pre-order in China

Pfizer Inc. (PFE) – Padcev Combination Therapy Receives FDA Priority Review for Expanded Bladder Cancer Indication - FCF Yield

Pfizer Inc. (PFE) – Padcev Combination Therapy Receives FDA Priority Review for Expanded Bladder Cancer Indication - Global Trading Community

Pfizer Inc. (PFE) - El precedente de fusiones y adquisiciones en oncología señala al sector al alza en medio de las conversaciones sobre la adquisición de Kelonia por parte de…

Pfizer Inc. (PFE) - Oncology M&A Precedent Signals Sector Upside Amid Eli Lilly’s Kelonia Acquisition Talks